Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin

Journal of Clinical Microbiology

Volumn 53, Issue 8, 2015, Pages 2727-2730

  Mendes, Rodrigo E ^a   Farrell, David J ^a   Flamm, Robert K ^a   Sader, Helio S ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELAVANCIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANALYTICAL ERROR; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; BROTH DILUTION; DRUG CLASSIFICATION; ENTEROCOCCUS FAECALIS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT AND TEICOPLANIN SUSCEPTIBLE ENTEROCOCCUS FAECALIS; DIAGNOSTIC ERROR; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ENTEROCOCCUS FAECALIS; STAPHYLOCOCCUS AUREUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DIAGNOSTIC ERRORS; ENTEROCOCCUS FAECALIS; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; VANCOMYCIN;

EID: 84938095898     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00611-15     Document Type: Article

References (7)

1. Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. 2014. Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) applying the revised susceptibility testing method. Antimicrob Agents Chemother 59:702-706. http://dx.doi.org/10.1128/AAC.04052-14.
2. Theravance Biopharma, Inc. 2014. Vibativ (telavancin) for injection, for intravenous use. Theravance Biopharma, Inc., South San Francisco, CA. http://www.vibativ.com/docs/VIBATIV-PI-Final.pdf.
3. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA. http://www.ncipd.org/UserFiles/CLSI-M100-S24.pdf.
4. EUCAST. 2014. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Breakpoint-tables/Breakpoint-table-v-4.0.pdf.
5. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA. http://antimicrobianos.com.ar/ATB/wp-content/uploads/2012/11/03-CLSI-M07-A9-2012.pdf.
6. Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters, 3rd ed. CLSI document M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Mendes RE, Farrell DJ, Sader HS, Streit JM, Jones RN. 2015. Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method. Diagn Microbiol Infect Dis 81:275-279. http://dx.doi.org/10.1016/j.diagmicrobio.2014.12.011.